Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.
|Articles|July 15, 2006
The American Journal of Managed Care
- July 2006
- Volume 12
- Issue 7
Brixner (Am J Manag Care. 2006;12[suppl 7]:S191-S198)
Advertisement
Am J Manag Care.
There were 2 errors in the supplement, "Fracture Prevention in Osteoporosis." First, in Figure 1 on page S192 of the article "Assessment of the Prevalence and Costs of Osteoporosis Treatment Options in a Real-world Setting," by Diana Brixner, PhD, RPh,(2006;12[suppl 7]:S191-S198), the bars representing the VERTNA [Vertebral Efficacy With Risedronate Therapy-North America] study were inadvertently switched with the placebo bars. Second, in the same figure, the acronym VERT-MIN was incorrect; the correct acronym is VERT-MN [Vertebral Efficacy With Risedronate Therapy-Multinational]. The corrected figure appears below.
Articles in this issue
over 20 years ago
Selecting an appropriate comparator to measure osteoarthritic painover 20 years ago
Defending Computerized Physician Order Entry From Its SupportersAdvertisement
Related to this article
Machine learning prediction of procalcitonin positivity using inexpensive routine laboratory tests may reduce procalcitonin test volume and support diagnostic stewardship.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.
Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.
The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
IVF Beats IUI for Early Live Births in Unexplained Infertility
4
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
5